The Centre for Drug Candidate Optimisation (CDCO) is a collaborative research centre based within the Monash Institute of Pharmaceutical Sciences.
We provide expertise and infrastructure in physicochemical property evaluation, drug metabolism and pharmacokinetics to multidisciplinary drug discovery teams for improved compound design, selection and progression.
Established in 2003, we have collaborated with numerous drug discovery groups that have progressed 28 novel drug candidates into clinical development across disease indications including cancer, CNS disorders, cardiovascular disease and infectious diseases.
Located within the Melbourne Biomedical Precinct, the CDCO occupies custom designed offices and laboratories, equipped with state-of-the-art instrumentation necessary to deliver on a wide range of in silico, in vitro and in vivo capabilities.
The CDCO's quality management system has been certified to ISO9001. We undertake high-quality research to industry standards to meet project goals and objectives.
We hold long standing relationships with global PDPs including Medicines for Malaria Venture (MMV) and the Drugs for Neglected Diseases Initiative (DNDi). Through these collaborations, five clinical candidates and a number of preclinical candidates have been delivered.